{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03134118\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab"]],"indication":"previously treated type B3 thymoma and thymic carcinoma","name":"NIVOTHYM","nct_id":"NCT03134118","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nivothym-nct03134118. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NIVOTHYM","arms":[{"description":"Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks","label":"Nivolumab","type":"EXPERIMENTAL"}],"collaborators":["ETOP IBCSG Partners Foundation"],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Thymoma Type B3","Thymic Carcinoma"],"enrollment":{"count":55,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":["BMS-936558-01"],"type":"DRUG"}],"last_update":"2026-05-15","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","official_title":"Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-09-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival Rate (PFSR) at month 6","timeFrame":"The Progression Free Survival Rate (PFSR) analysis will be performed at month 6"}],"references":[{"citation":"Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabe R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20.","pmid":"34393061","type":"DERIVED"}],"start_date":{"date":"2018-04-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)","url":"https://clinicaltrials.gov/study/NCT03134118"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nivothym-nct03134118"}